Ironwood Pharmaceuticals Inc. has maintained its financial guidance for fiscal year 2025 and introduced its outlook for 2026, projecting significant growth in key performance metrics. For 2025, the company expects LINZESS U.S. net sales in the range of $860 million to $890 million, with total revenue between $290 million and $310 million, and adjusted EBITDA exceeding $135 million. Looking ahead to 2026, Ironwood forecasts a notable increase in LINZESS U.S. net sales to between $1.125 billion and $1.175 billion, driven by improved net price and low-single digit percentage demand growth. Total revenue is anticipated to rise to $450 million to $475 million, and adjusted EBITDA is projected to surpass $300 million, reflecting disciplined expense management and the positive impact of strategic initiatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ironwood Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260102763645) on January 02, 2026, and is solely responsible for the information contained therein.